Stock comparison
IDEXX Laboratories
Organon &
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
OGN
Organon &
Market cap
$3.52B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | OGN | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 51C | IDXX |
| Benjamin Graham | 72B | 72B | Tie |
| Philip Fisher | 67B | 32F | IDXX |
| Peter Lynch | 63C | 21F | IDXX |
| Joel Greenblatt | 75B | 15F | IDXX |
| Charlie Munger | 79B | 42D | IDXX |
| Terry Smith | 76B | 40D | IDXX |
Side-by-side metrics
| Metric | IDXX | OGN |
|---|---|---|
| Market cap | $42.11B | $3.52B |
| P/E (TTM) | 39.0x | 14.2x |
| EV/EBIT | 31.6x | 8.5x |
| ROIC (TTM) | 40.66% | 5.16% |
| Gross margin | 62.05% | 53.11% |
| Net margin | 24.63% | 3.99% |
| Revenue CAGR 5y | 7.56% | -0.35% |
| EPS CAGR 5y | 10.79% | -39.38% |
| Debt / Equity | 0.7x | 9.5x |
| Dividend yield | 0.0% | 0.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- EPS CAGR 5y10.79%vs -39.38%+127%
- Revenue CAGR 5y7.56%vs -0.35%+105%
- Debt / Equity0.7xvs 9.5x+93%
- Market cap$42.11Bvs $3.52B+92%
OGN leads on
- Dividend yield0.6%vs 0.0%+100%
- EV/EBIT8.5xvs 31.6x+73%
- P/E (TTM)14.2xvs 39.0x+64%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.